CenterBook Partners
NKTR icon

CenterBook Partners’s Nektar Therapeutics NKTR Stock Holding History

CenterBook Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.6M Buy
+26,346
New +$1.85M 0.07% 333
2026
Q2 		– Sell
-7,407
Closed -$533K – 820
2026
Q1 		$533K Buy
+7,407
New +$422K 0.03% 473

Other funds holding NKTR

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
APEIRON Capital Ltd
APEIRON Capital Ltd Hong Kong $73.7M AUM 81.83% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

CenterBook Partners's NKTR Position: Q3 2026 in Review

CenterBook Partners opened a new position in Nektar Therapeutics (NKTR) in Q3 2026: 26,346 shares worth $1.6M. The stake represents 0.07% of the portfolio and ranks #333 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in NKTR as recently as Q1 2026.

CenterBook Partners first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • CenterBook Partners held 26,346 shares of Nektar Therapeutics worth $1.6M as of Q3 2026.
  • Nektar Therapeutics was a new CenterBook Partners position in Q3 2026.
  • Nektar Therapeutics made up 0.07% of CenterBook Partners's portfolio in Q3 2026, its #333 holding.
  • CenterBook Partners first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.